Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
21.90
-0.22 (-0.99%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Exelixis Inc
< Previous
1
2
3
4
5
Next >
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 01, 2023
From
Exelixis, Inc.
Via
Business Wire
7 Best Cancer Stocks to Invest in Now
July 28, 2023
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now.
Via
MarketBeat
Topics
Death
Exposures
Death
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
July 23, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
July 18, 2023
From
Exelixis, Inc.
Via
Business Wire
Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board
May 31, 2023
From
Farallon Capital Management L.L.C.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
May 30, 2023
From
Exelixis, Inc.
Via
Business Wire
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
May 18, 2023
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Via
MarketBeat
Exposures
Product Safety
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
From
Exelixis, Inc.
Via
Business Wire
Farallon Capital Management Comments on Successful Campaign for Change at Exelixis
May 07, 2023
From
Farallon Capital Management L.L.C.
Via
Business Wire
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
May 07, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
May 03, 2023
From
Exelixis, Inc.
Via
Business Wire
Farallon Capital Urges Exelixis Shareholders to Support Change by Electing Its Three Highly Qualified Director Candidates
May 03, 2023
From
Farallon Capital Management L.L.C.
Via
Business Wire
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
May 01, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
April 25, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis Advances Board Refreshment Plan
April 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis Reiterates Commitment to Shareholder Value Creation
April 05, 2023
From
Exelixis, Inc.
Via
Business Wire
Farallon Issues Letter to Exelixis Board of Directors Outlining Case for Change
April 05, 2023
From
Farallon Capital Management L.L.C.
Via
Business Wire
Exelixis Announces $550 Million Share Repurchase Program
March 20, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
March 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
March 02, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
February 28, 2023
From
Exelixis, Inc.
Via
Business Wire
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
February 13, 2023
From
Bristol Myers Squibb and Exelixis, Inc.
Via
Business Wire
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
February 13, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 07, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
February 02, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
January 24, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Update on Patent Litigation with MSN Laboratories
January 19, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
January 08, 2023
From
Exelixis, Inc.
Via
Business Wire
Four Undervalued Healthcare Stocks for 2023
January 06, 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Via
MarketBeat
Exposures
COVID-19
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —
January 03, 2023
From
Exelixis, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.